Drug intelligence / Profile preview

BE-105

Development stage: Preclinical
Lead developer: BiomEdit
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics

Overview

BE-105 is a preclinical, bacterial vectored therapeutic in development by BiomEdit for veterinary use. It is designed to modulate body weight and glucose metabolism in cats and is listed under the company's 'Breakthrough Projects' pipeline. [1]

Beyond the preview

Go deeper on BE-105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BE-105.

Explore the full profile